Higher antidepressant dose may raise risks for seniors with weak kidneys

NCT ID NCT07387120

Completed Knowledge-focused Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at nearly 7,000 older adults (65+) with low kidney function who started taking the antidepressant sertraline. Researchers compared the safety of a 50 mg daily dose versus a 25 mg daily dose, tracking hospital visits, emergency department visits, or death within 30 days. The goal was to see if the higher dose poses greater risks in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sertraline
What this could lead to: If successful, this could help doctors choose safer antidepressant doses for older adults with kidney problems.
What could go wrong: This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (CKD) ELDERLY OUTPATIENT

Contacts and locations

Locations

London Health Sciences Centre Research Institute

London, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.